Phoenix Tissue Repair, an affiliate company of BridgeBio Pharma, reported positive findings from the Phase II clinical trial of recombinant collagen 7 (rC7) protein replacement therapy, PTR-01, in people with recessive dystrophic epidermolysis bullosa (RDEB).

In 2017, Phoenix obtained global rights to PTR-01, an investigational drug candidate intended to be systemically available through intravenous administration.

The open-label trial analysed the impact of PTR-01 on healing wound and other endpoints.

It also assessed the long-term safety and tolerability of the drug.

According to the trial findings, PTR-01 was demonstrated to be well tolerated when administered once a week for four weeks and followed by every alternative week for 14 weeks.

Furthermore, PTR-01 treatment offered quick, consistent and long-lasting wound healing as observed in decline of wound surface area and clinician-reported analyses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

More than 80% of target wounds showed a 50% or higher decline in wound surface area by day 120 of the treatment versus baseline.

Subject-reported outcomes assessing pain, essential function, mood, daily living activities and impact of disease demonstrated noticeable mean and median decline at the end of the trial versus baseline.

Over the course of treatment with the investigational drug, all subjects who completed the trial had a decline in pain.

At the end of the trial, a 36% mean decline in total pain as assessed on the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB) subject reported subdomain scale versus baseline was reported.

In addition, systemic dosing with PTR-01 offered a quick rC7 deposition at the DEJ during the loading phase and was present for up to three months following treatment.

Phoenix Tissue Repair executive chairman Sanuj Ravindran said: “In patients with recessive dystrophic epidermolysis bullosa (RDEB) even minor friction or trauma can cause debilitating blistering, tearing and scarring of the skin, along with severe pain and itching.

“Our data shows that treatment with PTR-01 led to rapid, consistent, and durable wound healing.”

With the latest development, the company has commenced a Phase II extension trial.

In July last year, BridgeBio signed a clinical partnership to evaluate BBP-398 plus Bristol Myers Squibb’s Opdivo (nivolumab) for the treatment of advanced solid tumours with KRAS mutations.